GPCRs in Oncology and Immunology Olfactory Receptors and Tumorigenesis: Implications for Diagnosis and Targeted Therapy Published date October 4, 2024 Abstract "Olfactory receptors (ORs) are a class of G protein-coupled The potential for precise tumor diagnosis and targeted therapy through therapeutic targeting of olfactory , Chun-Xia Zhang, Guo-Tai Wang Tags G Protein-coupled receptors , Olfactory receptors , Therapeutic targeting

Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy Published date November 1, 2022 Abstract Pancreatic ductal adenocarcinoma (PDAC) remains an As therapeutic options are limited, novel targets, and agents for therapeutic intervention are urgently

EGFR and SSTR2, and EGFR/SSTR2 anyone high expression had a better prognosis with CR combined with targeted therapy. relationship between SSTR2 and EGFR in NPC and provides new insights into the potential benefits of EGFR targeted therapy for patients with high SSTR2 expression.

the PKA-Hippo signaling pathway Published date March 2, 2024 Abstract " Background: Novel therapeutic targets treating drug-resistant non-small cell lung cancer (NSCLC) and overcoming drug resistance to molecular-targeted therapies. These insights support the role of RGS20 as a promising novel molecular marker and a target for future targeted therapies in lung cancer treatment."

< GPCR News < GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages Published date May 28, 2023 promotes the secretion of chemokines and polarizing factors through activating PI3K/AKT/NF-κB pathway, thereby Tags A2aR , Lung adenocarcinoma , Migration , Polarization , Targeted therapy , Tumor-associated macrophages

Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target therapy, and clear understanding of disease etiology. Results show that the elevated expression of UCA1 enhances cell proliferation, invasive migration, and therapy UCA1 expression inversely correlates with survival outcomes and therapy response in ovarian cancer clinical Tags GPCR , High Grade Serous Ovarian Carcinoma , Let-7 miRNAs , Oncogenic Pathways , Ovarian Cancer , Therapy

Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1, a GPCR which is reported to be overexpressed in ovarian cancer cells, was identified as a target This established Peptidase M84 as a drug candidate for receptor mediated targeted-therapy of ovarian

< GPCR News < GPCRs in Oncology and Immunology The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy Published date September 12, 2024 Abstract Despite their crucial role in regulating antitumor immunity and tumorigenesis, therapeutic applications targeting The review culminates by illuminating emerging therapies and discussing innovative strategies to harness the full potential of GPCR-targeted treatments, by applying a multireceptor and patient-specific logic

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Targeting immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer target Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several

< GPCR News < GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases Tags CCR6 , GPCRs , Th17 cells , antibody , immune system , inflammation , therapy .

< GPCR News < GPCRs in Oncology and Immunology Elucidation of active components and target mechanism Aim of the study: We hypothesized that Jinqiancao granules could be a potential therapy for prostatitis and BPH, and this work aimed to elucidate active compounds in Jinqiancao granules and their target mechanisms Five compounds showed weak antagonistic activity on M3, which was confirmed to be a disease target by Several compounds showed multi-target properties.

< GPCR News < GPCRs in Oncology and Immunology Emerging GPCR targets for AUD: Insights from preclinical Currently, many drugs available on the market act via GPCRs and these receptors remain attractive targets Here, we describe the most recent literature, with a primary focus on the past 5 years, on GPCR targets

Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer: Novel Precision Targeted

< GPCR News < GPCRs in Oncology and Immunology Small-molecule targeting of GPCR-independent noncanonical Gαβγ) by G-protein-coupled receptors (GPCRs) is a quintessential mechanism of cell signaling widely targeted G-proteins can also be activated via GPCR-independent mechanisms that remain untapped as pharmacological targets IGGi-11 binding to G-protein α-subunits (Gαi) specifically disrupted their engagement with GIV/Girdin, thereby these findings warrant the exploration of therapeutic modalities in G-protein signaling that go beyond targeting

< GPCR News < GPCRs in Oncology and Immunology Identification of Small-Molecule Antagonists Targeting The GHRHR has recently been highlighted as a promising drug target toward several types of cancer and However, no nonpeptide GHRHR-targeting compounds have yet been identified. We have utilized several computational tools to target GHRHR and identify potential small-molecule compounds

< GPCR News < GPCRs in Oncology and Immunology G Protein-coupled Receptor-mediated Membrane Targeting The study reveals a molecular mechanism of membrane targeting of PLCγ2 and the signaling pathways by

< GPCR News < GPCRs in Oncology and Immunology Unveiling G-protein coupled receptors as potential targets Currently, very few G-protein coupled receptors (GPCRs) have been investigated for active targeting with include the identification of unique GPCRs expressed in cancer biopsies, matched with personalised GPCR-targeted therefore, supporting and emphasising the need for the future development of case-to-case personalised targeting

Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy complication after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy We evaluated infections in 99 adults who received a first BCMA-directed CAR T-cell therapy (commercial Respiratory infections predominate after BCMA CAR T-cell therapy, particularly after day 100. early respiratory infection are risk factors for late respiratory infections that may be used to guide targeted

Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy extracellular ATP (e-ATP) and ADO effects on the TME poses challenges in identifying optimal treatment targets This review explores e-ATP metabolism, its purinergic signaling, and therapeutic strategies targeting

These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand

These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand

GPCR News < GPCRs in Oncology and Immunology Comparison of infectious complications with BCMA-directed therapies in multiple myeloma Published date May 31, 2024 Abstract "B-cell-maturation-antigen (BCMA)-directed therapies In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates Comparing T-cell redirecting therapies, the incidence rate of severe infections was significantly lower

and Immunology Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets various sensory and autonomic pathologies in type 2 inflammatory diseases and present recent advances in targeted

Understanding the signaling pathways involved in cancer progression is essential for the discovery of new drug targets cancer types; however, AC overactivation, along with that of downstream regulators, presents a potential target for novel anticancer therapies.

5 member D (GPRC5D), an orphan GPCR predominantly expressed in MM cells, is emerging as a promising target and Drug Administration-approved T-cell-directing bispecific antibody developed for treatment of MM, targets structure offers insights for optimizing antibody design against GPRC5D for relapsed or refractory MM therapy

In the past, studies predicting therapeutic drug targets for cancer therapy focused on the assumption Therefore, there is always an immense need to find promising and novel anti-cancer drug targets. inactive rhomboid protease known as iRhom2 encoded by the gene RHBDF2 can be considered an important target

perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target example of our recent work surrounds a structure-based effort to develop ligands that specifically target Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy We have identified several GPCR ligands that allosterically modulate orthosteric ligand binding and target Again, our intention is to target specific receptor subtypes.

< GPCR News < GPCRs in Oncology and Immunology G protein-coupled receptors: A target for microbial metabolites